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Available online xxxxBackground: People with schizophrenia have high rates of substance use which contributes to co-morbidity and
premature mortality. Some evidence suggests people at-risk for psychosis have high rates of substance use. We
aimed to assess substance use in a help-seeking cohort, comparing those at-risk and not at-risk for psychosis, and
to establish any relationship with clinical symptoms.
Method: Participants were help-seeking youth presenting to mental health services in Sydney and Melbourne.
279 (34.8%) were at-risk for psychosis, and 452 (56.4%) did not meet criteria for a psychotic disorder or risk
for psychosis. The excluded individualsweremade up of 59 (7.4%) young peoplewhomet criteria for a psychotic
disorder and 11 (1.4%) who were unable to be evaluated. We assessed the association of substance use involve-
ment with risk status and clinical symptoms using multivariate regression.
Results: Individuals at-risk for psychosis had signiﬁcantly higher tobacco, alcohol and cannabis use than those not
at-risk.Multivariate analysis revealed at-risk statuswas signiﬁcantly associatedwith higher alcohol involvement
scores when adjusting for age and gender, but no association was found for cannabis or tobacco. At-risk status
was no longer associated with alcohol involvement when cannabis or tobacco use was added into the analysis.
Conclusion: Tobacco smoking, alcohol consumption and cannabis use are common in help-seeking youth, partic-
ularly those at-risk for psychosis. It is important to consider co-occurring use of different substances in adoles-
cents. Early substance misuse in this phase of illness could be targeted to improve physical and mental health
in young people.
© 2016 Published by Elsevier B.V.Keywords:
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People with schizophrenia have high rates of substance use includ-
ing tobacco, alcohol and cannabis use (Addy et al., 2012; Davidson
et al., 2001; McCreadie, 2003). This increases the risk of later cardiovas-
cular disease. Together with themetabolic side effects of antipsychotics,
these unhealthy lifestyle factors contribute to the increased morbidity
and premature mortality of this population, (De Hert et al., 2011; Saha
et al., 2007; Wahlbeck et al., 2011). High rates of substance use are ob-
served early in the illness course, in individuals with ﬁrst-episode psy-
chosis (FEP) (Barnett et al., 2007; Wade et al., 2006).r and Mental Health, University
ord Road, Manchester M13 9PL,
.ac.uk (R. Carney).
Substance use in youth at riThe ultra-high risk state (UHR), also called the prodromal, clinical
high-risk (CHR) or at-risk mental state (ARMS) (Fusar-Poli et al.,
2013), identiﬁes people at imminent high risk of developing a psychotic
disorder, that is, theymay be in in the prodromal phase for psychosis. In
order to meet UHR status an individual must exhibit one or a combina-
tion of the following characteristics: presence of attenuated psychotic
symptoms, brief intermittent psychotic symptoms, or a genetic-risk
combined with a recent decline in functioning (Yung et al., 2004).
These are assessed with established criteria (Miller et al., 2002; Yung
et al., 2002; Yung and McGorry, 1996; Yung et al., 1998).
Two recent reviews suggest UHR individuals have high rates of poor
physical health and unhealthy lifestyle behaviours such as smoking,
cannabis and alcohol use (Addington et al., 2014; Carney et al., 2016).
In at-risk samples, more severe symptoms are also associated with
higher levels of substance use (Auther et al., 2012; Svirskis et al.,
2005). Previous research has indicated that cannabis signiﬁcantlysk for psychosis, Schizophr. Res. (2016), http://dx.doi.org/10.1016/
2 R. Carney et al. / Schizophrenia Research xxx (2016) xxx–xxxincreases the risk for psychosis, with the greatest risk associated with
early age of ﬁrst use (Donoghue et al., 2014; Helle et al., 2016), use of
high potency cannabis or ‘skunk’(Di Forti et al., 2014; Marconi et al.,
2016) and in those with an underlying genetic predisposition for psy-
chosis (Henquet et al., 2008). Additionally, recent meta-analyses sug-
gest there is a dose-response relationship between heavy cannabis use
and transition to psychosis in UHR individuals (Kraan et al., 2015).
Despite these ﬁndings, there is little research into physical health
and associated risk behaviours in UHR youth and these factors are poor-
ly monitored in clinical services (Carney et al., 2015). Studies assessing
lifestyle factors in UHR individuals rarely have substance use as a prima-
ry outcome. Those that do are often underpowered, with small samples
(Allen et al., 2014; Rapp et al., 2013). Additionally, many fail to include
an adequate control group (Dragt et al., 2012; Kristensen and
Cadenhead, 2007; Phillips et al., 2002; Rapp et al., 2013) and often use
unvalidated measurement tools (Stone et al., 2012; van Tricht et al.,
2013). There is also a lack of evidence to link psychological and psycho-
social factors to rates of substance use, as this has not yet been assessed
in large cohorts.
To address this gap we aimed to;
(1) Assess rates of substance use, in help seeking individuals, to es-
tablish whether those with a speciﬁc risk for psychosis have
higher rates of substance involvement than those without,
using a World Health Organisation substance use assessment
tool (ASSIST; (WHO, 2002)) This tool measures degree of sub-
stance involvement, taking into account current and lifetime
use of substances, frequency of use, desire, problematic use, fail-
ure tomeet expectations, concern expressed by others and failed
attempts to quit.
(2) Identify any relationship between substance involvement, clini-
cal symptoms and other psychosocial variables.Fig. 1. Flow diagram of individu
Please cite this article as: Carney, R., et al., Substance use in youth at ri
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2.1. Participants and setting
Data from the Transitions Study (Purcell et al., 2014) were used to
conduct a cross-sectional analysis of a help-seeking cohort presenting
at youth mental health services in Australia. The Transitions Study has
been described in detail elsewhere (Purcell et al., 2015; Purcell et al.,
2014). Participants were help-seeking individuals aged 12–25 years
who had engaged with one of four ‘headspace’ clinics in Melbourne
and Sydney, Australia, between January 2011 and August 2012
(Rickwood et al., 2014). ‘headspace’ was established by the Australian
Government to provide mental health services for young people. Of
1615 individuals receiving help from these services, 801 young people
consented to participate in the study, of whom 279 were at-risk for
psychosis, 59 had established psychotic disorder and 452 met neither
psychosis risk nor psychosis criteria (at-risk for psychosis status could
not be evaluated in 11 participants) (Fig. 1), (Purcell et al., 2014).
Those who could not be evaluated or who had a psychotic disorder
were excluded, leaving 731 individuals.2.2. Procedure
Baseline assessment measures were administered after participants
gave informed consent Research assistants (RAs) with a minimum of
4-years graduate psychology degrees administered assessments. RAs
had very good (kappa N 0.8) inter-rater reliability on interviewer-
rated measures. Self-report measures were completed by participants
on an iPad. A $20 gift voucher was provided to each participant. The
Human Research Ethics Committees at the University of Melbourne
and University of Sydney approved the study.als included in the analysis.
sk for psychosis, Schizophr. Res. (2016), http://dx.doi.org/10.1016/
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The Positive Symptom Scale of the Comprehensive Assessment for
At-Risk Mental State (CAARMS) (Yung et al., 2005) was used to deter-
mine whether an individual was at-risk for psychosis. This consists of
four subscales: (i) unusual thought content; (ii) non-bizarre ideas;
(iii) perceptual abnormalities; and (iv) disorganised speech. Scores for
each of the subscales are rated according to intensity, frequency and du-
ration of symptoms. An individual was considered at-risk of psychosis if
they scored above a pre-set threshold on both intensity and frequency
on any of these subscales, consistent with previous deﬁnitions (Yung
et al., 2004).
Further clinician rated measures included; 16-item adolescent ver-
sion of the Quick Inventory of Depressive Symptomatology (QIDS,
(Rush et al., 2003)), Social and Occupational Functioning Assessment
Scale (SOFAS, (Morosini et al., 2000)), and Young Mania Rating Scale
(YMRS, (Young et al., 2000)). Self-report clinical measures included;
Kessler 10 (K10, (Andrews and Slade, 2001)), Somatic and Psychologi-
cal Health Report (SPHERE 12, (Berryman et al., 2012)), Generalised
Anxiety Disorder scale (GAD-7, (Spitzer et al., 2006)), Overall Anxiety
Severity and Impairment Scale (OASIS (Campbell-Sills et al., 2009)),
WHO Disability Assessment Schedule (WHODAS-12, (Üstün, 2010)), a
question on quality of life taken from the WHOQOL, (Group, T.W,
1998) and a 5-item eating disorder screening tool (SCOFF, (Morgan
et al., 1999)). Substance use was assessed using the WHO Alcohol,
Smoking and Substance Involvement Screening Test (WHO-ASSIST,
(WHO, 2002)). Personality characteristics were assessed using the
Behavioural Inhibition/Activation Scale, (BIS/BAS, (Carver and White,
1994)).
2.4. Statistical analysis
Categorical variables were analysed using a χ2 test and continuous
variables were compared using t-tests. When the assumptions for para-
metric statistics were violated, determined by distribution of data on
histograms, non-parametric tests were employed (such as MannWhit-
ney U). Current use of substances was deﬁned as use within the past
threemonths (WHO, 2002). Use of substances other than tobacco, alco-
hol and cannabis was minimal; therefore, data was not included in fur-
ther analysis. Substance involvement was calculated by taking into
account current and lifetime use of substances, frequency of use, desire,
problematic use and failure to meet expectations, concern expressed by
others and failed attempts to quit.
Regression analyses were performed on the whole sample using
each of the substance involvement scores (alcohol, tobacco and canna-
bis) as the dependent variables and risk-status, demographic informa-
tion and clinical variables as independent variables (predictors).
Where the outcome data was skewed, quantile median regression was
used (alcohol and tobacco involvement). Predictors of cannabis involve-
mentweremodelled usingmean regression, asmedian quantile regres-
sion models failed to converge. The clinical variables used in the
multivariate analysis related to clinically signiﬁcant outcomes such as
depression, psychological distress, anxiety and functioning. Personality
characteristics and symptoms of mania or eating disorders were there-
fore, excluded from the multivariate analysis, as they were deemed
non-signiﬁcant clinical variables. A signiﬁcance level of 0.05 was used
for all statistical tests, and two-tailed tests were applied. All data analy-
sis was conducted using SPSS 22.0 (IBM, 2013).
3. Results
The sample consisted of young people presenting to youth mental
health services in Australia. Individuals at-risk for psychosis and help-
seeking controls did not differ according to age (psychosis risk 18.19;
help-seeking control 18.33), or gender ratio (see Table 1). A higher pro-
portion of females than males was found in both groups (psychosis riskPlease cite this article as: Carney, R., et al., Substance use in youth at ri
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‘headspace’ cohort (Rickwood et al., 2014).
3.1. Substance use in individuals at-risk for psychosis compared to
help-seeking controls
3.1.1. Tobacco
Tobacco involvement scores were signiﬁcantly higher in individuals
at-risk for psychosis (7.90) than help-seeking controls (5.94; p= 0.01).
Scores 0–3 indicate low risk, 4–26 moderate risk and 27 or higher sug-
gests high risk. Compared to help-seeking controls, those at-risk for psy-
chosis were more likely to have high risk tobacco use (5%, 1%; X2 =
(1)12.79, p=0.001;OR7.28, 95%CI 2.06, 25.79), daily, lifetime and cur-
rent tobacco use. Problematic use (at least weekly use of tobacco) was
not signiﬁcantly different between the groups.
3.1.2. Alcohol
Individuals at-risk for psychosis had signiﬁcantly higher alcohol in-
volvement (6.40) than help-seeking controls (5.16; p = 0.01). Scores
0–10 indicate low risk, 11–26 moderate risk and 27 or higher suggests
high risk. High-risk alcohol use was no different between groups (2%).
No differences were found between groups for current, daily, problem-
atic, or lifetime use.
3.1.3. Cannabis
Those at-risk for psychosis had higher cannabis involvement scores
(4.45) than help-seeking controls (3.20; p = 0.02). The criteria for
low, moderate and high risk cannabis use were the same as tobacco
use. Individuals at-risk for psychosis had higher rates of high risk canna-
bis use (psychosis risk 4.7%, help-seeking controls 1.6%) and moderate
risk cannabis use (psychosis risk 25.4%, help-seeking controls 21.2%;
X2= (2) 8.67, p= 0.01). Signiﬁcantlymore participants at-risk for psy-
chosis used cannabis in their lifetime, and currently used cannabis
(33%), than help-seeking controls (26%). Problematic use was higher
in those at-risk (16.1%) than help-seeking controls (14.4%) but the dif-
ference was not signiﬁcant.
3.2. What predicts substance use in help-seeking youth?
Regression analyses controlling for at-risk status, age and gender can
be found in Table 2. Independent of group (at risk or not at risk), sub-
stance involvement was associated with a range of clinical factors. For
example, across the whole sample, a reduction in quality of life was as-
sociated with increased alcohol (b=−0.47, 95% CI−0.82,−0.12), to-
bacco (b =−1.24, 95% CI−2.34,−0.14) and cannabis involvement
(b=−0.94, 95% CI−1.45,−0.44). An increase in depressionwas asso-
ciated with increased substance involvement scores across the whole
group; however, there was no association for anxiety (Table 2).
At-risk status was independently associated with a 0.90 increase in
median alcohol involvement score after adjusting for age, gender and
clinical variables (b = 0.90, 95% CI 0.11, 1.69). However, no signiﬁcant
association was found for tobacco use or cannabis involvement
(Table 3).
Building on the initial analysis (Table 3), use of other substanceswas
factored into the regression for alcohol involvement. Further multivari-
ate analyses showed that at-risk status was no longer predictive of alco-
hol involvement scores when adjusted for tobacco (b = 0.51, 95% CI
−0.34, 1.36), or cannabis use (b = 0.67, 95% CI−0.19, 1.52), as both
scores signiﬁcantly predicted alcohol use (Table 4). Additionally, no sig-
niﬁcant interactionswere found between at-risk status and tobacco use,
or at-risk status and cannabis use.
4. Discussion
In our large sample of help-seeking youth, those at-risk for psychosis
had signiﬁcantly higher tobacco, alcohol and cannabis use than help-sk for psychosis, Schizophr. Res. (2016), http://dx.doi.org/10.1016/
Table 1
ASSIST substance use analysis in help-seeking youth at risk and not at risk for psychosis.
At risk for psychosis (n = 279) Not at risk for psychosis (n = 450) Statistic
Age: mean (S.D) 18.19 (3.16) 18.33 (3.32) t (729) = 0.58, 95% CI (−0.35, 0.63)
Gender: (% female) 66.7% (186) 65.7% (297) ×2 = 0.071, df 1, p = 0.79, OR 1.04, 95% CI (0.76, 1.43)
Tobacco
ASSIST tobacco involvement: mean (S.D) 7.90 (9.38) 5.94 (7.88) U = 56,450, p = 0.01
Lifetime use: yes (%) 196 (70.3%) 284 (62.8%) ×2 = 4.21, df1, p = 0.04, OR 1.4, 95% CI (1.01, 1.92)
Current use: yes (%) 145 (52%) 205 (45.4%) ×2 = 3.027, df1, p = 0.08, OR 1.3, 95% CI (0.97, 1.76)
Daily use: yes (%) 101 (36.2%) 127 (28.1%) ×2 = 5.278, df1, p = 0.02, OR 1.5, 95% CI (1.06, 2.00)
Problematic use: yes (%) 113 (40.5%) 159 (58.5%) ×2 = 2.094, df1, p = 0.15, OR 1.3, 95% CI (0.92, 1.71)
Alcohol
ASSIST alcohol involvement: mean (S.D) 6.40 (6.84) 5.16 (6.25) U = 55,644, p = 0.01
Lifetime use: yes (%) 244 (87.5%) 373 (82.5%) ×2 = 3.189, df1, p = 0.07, OR 1.5, 95% CI (0.96, 2.27)
Current use: yes (%) 196 (70.3%) 300 (66.4%) ×2 = 1.190, df1, p = 0.28, OR 1.2, 95% CI (0.87, 1.65)
Daily use: yes (%) 20 (7.2%) 22 (4.9%) ×2 = 1.687, df1, p = 0.19, OR 1.5, 95% CI (0.81, 2.81)
Problematic use: yes (%) 97 (34.8%) 138 (30.5%) ×2 = 1.419, df1, p = 0.23, OR 1.2, 95% CI (0.88, 1.67)
Cannabis
ASSIST cannabis involvement: mean (S.D) 4.45 (7.99) 3.20 (6.55) U = 57,468, p = 0.02
Lifetime use: yes (%) 157 (56.3%) 210 (46.5%) ×2 = 6.644, df1, p = 0.01, OR 1.5, 95% CI (1.09, 2.00)
Current use: yes (%) 93 (33.3%) 119 (26.3%) ×2 = 4.112, df1, p = 0.04, OR 1.4, 95% CI (1.01, 1.94)
Daily Use: yes (%) 25 (9.0%) 34 (7.5%) ×2 = 0.481, df1, p = 0.49, OR 1.2, 95% CI (0.71, 2.08)
Problematic Use: yes (%) 45 (16.1%) 65 (14.4%) ×2 = 0.413, df1, p = 0.52, OR 1.1, 95% CI (0.76, 1.73)
Cocaine
ASSIST cocaine involvement: mean (S.D) 0.24 (1.72) 0.26 (1.42) U = 62,664, p = 0.19
Lifetime use: yes (%) 40 (14.4%) 74 (16.4%) ×2 = 0.514, df1, p = 0.47, OR 0.9, 95% CI (0.56, 1.30)
Amphetamines
ASSIST amphetamine involvement: mean (S.D) 1.12 (3.74) 0.75 (3.02) U = 59,974, p = 0.11
Lifetime use: yes (%) 80 (28.8%) 104 (23%) ×2 = 3.038, df1, p = 0.08, OR 1.4, 95% CI (0.96, 1.91)
Sedatives
ASSIST sedative involvement: mean (S.D) 0.09 (1.01) 0.12 (0.84) U = 59,974, p = 0.11
Lifetime use: yes (%) 43 (15.5%) 57 (12.6%) ×2 = 1.188, df1, p = 0.28, OR 1.3, 95% CI (0.83, 1.94)
Hallucinogens
ASSIST hallucinogen involvement: mean (S.D) 0.45 (2.063) 0.31 (2.01) U = 62,064, p = 0.28
Lifetime use: yes (%) 50 (18%) 75 (16.6%) ×2 = 0.235, df1, p = 0.63, OR 1.1, 95% CI (0.74, 1.63)
Inhalants
ASSIST inhalant involvement: mean (S.D) 0.51 (2.49) 0.33 (1.6) U = 62,365, p = 0.93
Lifetime use: yes (%) 22 (7.9%) 36 (8%) ×2 = 0.001, df1, p = 0.98, OR 1.0, 95% CI (0.57, 1.73)
Opioids
ASSIST opioid involvement: mean (S.D) 0.27 (2.04) 0.27 (2.10) U = 62,689, p = 0.65
Lifetime Use: yes (%) 15 (5.4%) 23 (5.1%) ×2 = 0.029, df1, p = 0.87, OR 1.1, 95% CI (0.54, 2.07)
Other
ASSIST other involvement: mean (S.D) 0.08 (0.54) 0.01 (0.14) U = 62,700, p = 0.58
Lifetime use: yes (%) 15 (5.4%) 11 (2.4%) ×2 = 4.355, df1, p = 0.04, OR 2.28, 95% CI (1.03, 5.03)
Abbreviations: S.D., standard deviation; ASSIST, Alcohol, Smoking and Substance Involvement Screening Test.
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after adjusting for clinical and demographic variables, but did not pre-
dict cannabis or tobacco scores. Additionally, UHR status was no longerTable 2
Regression analysis adjusting for UHR status, age and gender.
Alcohol involvement Toba
Clinical measure* all adjusted for
at-risk group, age and gender
Coefﬁcient p-Value 95% CI Coefﬁ
K10 0.03 0.14 −0.01–0.08 0.1
SPHERE Psych 6 0.02 0.69 −0.09–0.13 0.13
SPHERE Soma 6 0.13 0.02 0.02–0.23 0.17
GAD7 0.14 0.69 −0.05–0.08 0.05
OASIS −1.94 1.00 −0.08–0.08 −8.3
SCOFF 0.48 0.01 0.15–0.81 1.5
WHOQOL −0.47 0.01 −0.82 to−0.12 −1.2
WHODAS12 0.01 0.53 −0.03–0.06 0.14
QIDS 0.12 0.01 −0.04–0.20 0.24
SOFAS 0 1.00 −0.03–0.03 −0.0
YMRS 0.11 0.03 −0.01–0.20 0.4
BAS drive 2.78 1.00 −0.15–0.15 −0.0
BAS fun seeking −0.21 0.01 −0.36–0.06 −0.4
BAS reward 3.70 1.00 −0.14–0.14 0.07
BIS 0 1.00 −0.11–0.11 0.18
Abbreviations: BAS, Behavioural Activation Scale; BIS, Behavioural Inhibition Scale; GAD, Gener
ment Scale; QIDS, Quick Inventory of Depressive Symptomatology; SCOFF, 5-item eating disord
and Psychological Health Report (P-Psychological, S-Somatic);WHODAS,World Health Organis
Scale; YMRS, Youth Mania Rating Scale.
Please cite this article as: Carney, R., et al., Substance use in youth at ri
j.schres.2016.08.026independently associatedwith alcohol involvement after controlling for
tobacco and cannabis involvement scores, as these variables demon-
strated much stronger associations with alcohol involvement.cco involvement Cannabis involvement
cient p-value 95% CI Coefﬁcient p-value 95% CI
0.12 −0.27–0.23 0.07 0.01 0.02–0.13
0.40 −0.18–0.44 0.22 0.01 −0.07–0.36
0.32 −0.16–0.50 0.24 0.01 0.09–0.38
0.61 −0.15–0.25 0.08 0.08 −0.01–0.17
3 1.00 −0.24–0.24 0.08 0.14 −0.03–0.18
0.01 0.60–2.40 0.59 0.01 0.17–1.02
4 0.03 −2.34 to−0.14 −0.94 0.01 −1.45 to –0.44
0.03 0.02–0.26 0.09 0.01 0.03–0.15
0.03 0.02–0.46 0.22 0.01 0.12–0.33
7 0.14 −0.18–0.02 −0.11 0.01 −0.16–0.06
0.01 0.15–0.65 0.18 0.01 0.06–0.31
8 0.73 −0.51–0.36 −0.02 0.86 −0.21–0.17
0 0.05 −0.81–0.00 −0.28 0.01 −0.47–0.08
0.76 −0.36–0.50 −0.01 0.98 −0.20–0.19
0.27 −0.14–0.49 0.04 0.56 −0.10–0.18
alised Anxiety Disorder Scale, K10, Kessler 10; OASIS, Overall Anxiety Severity and Impair-
er scale; SOFAS, Social and Occupational Functioning Assessment Scale; SPHERE, Somatic
ation Disability Assessment Schedule;WHOQoL,World Health Organisation Quality of Life
sk for psychosis, Schizophr. Res. (2016), http://dx.doi.org/10.1016/
Table 3
Regression analysis of UHR status and substance involvement scores, adjusting for age, gender and clinical variables.
Variables Coefﬁcient p-Value 95% CI
Alcohol involvement score Model 1
At-risk status (UHR) 0.90 0.03 0.11–1.69
Sex (female) −0.08 0.84 −0.89–0.72
Age 0.61 0.01 0.49–0.72
K10 0.44 0.02 −0.28–0.12
WHOQOL −0.68 0.01 −1.15–0.21
WHODAS 0.03 0.36 −0.03–0.09
SOFAS 0.02 0.27 −0.02–0.06
OASIS −0.08 0.15 −0.19–0.03
SPHERE psych 6 −0.19 0.04 −0.36–0.01
SPHERE somatic 6 0.12 0.10 −0.02–0.26
Constant −7.51 0.01 −11.62–3.41
Tobacco involvement score Model 1
At-risk status (UHR) 0.52 0.68 −1.94–2.97
Sex (female) −0.43 0.74 −2.93–2.07
Age 0.51 0.01 0.15–0.87
K10 0.18 0.12 −0.05–0.40
WHOQOL −1.26 0.10 −2.73–0.22
WHODAS 0.08 0.40 −0.10–0.26
SOFAS −0.05 0.37 −0.16–0.06
OASIS −0.31 0.08 −0.66–0.04
SPHERE psych 6 −0.27 0.33 −0.83–0.28
SPHERE somatic 6 −0.04 0.85 −0.48–0.39
Constant −0.28 0.97 −13.06–12.50
Cannabis involvement score Model 1
At-risk status (UHR) 0.61 0.25 −0.45 – 1.75
Sex (female) 0.43 0.94 −1.08 – 1.16
Age 0.40 0.01 0.24–0.56
K10 −0.14 0.78 −0.11–0.86
WHOQOL −0.58 0.08 −1.25–0.08
WHODAS 0.03 0.55 −0.57–0.11
SOFAS −0.08 0.01 −0.13–0.03
OASIS −0.12 0.13 −0.18–0.31
SPHERE psych 6 0.07 0.59 −0.18–0.32
SPHERE somatic 6 0.16 0.11 −0.04–0.35
Constant 2.57 0.38 −3.17–8.32
Abbreviations: K10, Kessler 10; OASIS, Overall Anxiety Severity and Impairment Scale; SOFAS, Social and Occupational Functioning Assessment Scale; SPHERE, Somatic and Psychological
Health Report (P-Psychological, S-Somatic); uhr,Ultra-high risk for psychosis;WHODAS,WorldHealthOrganisationDisability Assessment Schedule;WHOQoL,WorldHealthOrganisation
Quality of Life Scale.
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polysubstance use is likely in both groups, and reﬂects observations
from the general population in this age group (Redonnet et al., 2012),
and the at-risk group (Auther et al., 2015). Both help-seeking groups
had higher rates of smoking and substance use than the general
Australian population (Scollo and Winstanley, 2008). For example, the
National Drug Strategy Household Survey 2013 reported 18.6% ofTable 4
Alcohol involvement score adjusting for tobacco and cannabis involvement.
Alcohol involvement score
Model Variables Co-efﬁcient p-Value 95% CI
Model 2 At-risk status (UHR) 0.51 0.24 −0.34–1.36
Tobacco involvement 0.24 0.01 −0.20–2.93
(+Model 1) – – –
Model 3 At-risk status (UHR) 0.75 0.21 −0.43–1.93
Tobacco involvement 0.25 0.01 0.18–0.32
Model 4 At-risk status (UHR) 0.33 0.66 −1.15–1.81
Tobacco involvement 0.22 0.01 0.13–0.32
Tobacco involvement × UHR 0.09 0.21 −0.05–0.22
Model 5 At-risk status (UHR) 0.67 0.13 −0.19–1.52
Cannabis involvement 0.22 0.01 0.16–0.28
(+Model 1) – – –
Model 6 At-risk status (UHR) 0.6 0.18 −0.27–1.47
Cannabis involvement 0.24 0.01 0.17–0.31
Cannabis involvement × UHR −0.04 0.47 −0.14–0.07
Model 7 At-risk status (UHR) 0.53 0.21 −0.31–1.38
Tobacco involvement 0.21 0.01 0.16–0.27
Cannabis involvement 0.08 0.01 0.02–0.15
Please cite this article as: Carney, R., et al., Substance use in youth at ri
j.schres.2016.08.026young people (18–24) currently smoked tobacco (AIHW, 2014), com-
pared with 52% of our at-risk sample and 45% help-seeking controls.
Our ﬁndings therefore support previous research reporting elevated
levels of substance use in help-seeking adolescents (Hermens et al.,
2013).
People with schizophrenia have high rates of smoking (de Leon and
Diaz, 2005), alcohol and cannabis use (Addy et al., 2012; Drake and
Mueser, 2002). Our ﬁndings support recent research suggesting risk fac-
tors for poor health and long term outcome occur prior to the onset of
psychosis (Addington et al., 2014; Carney et al., 2016). Substance use is
linked to poor psychological outcome and high rates of relapse in patient
groups (Hides et al., 2006; Lambert et al., 2005), particularly in individ-
uals who continue to use substances after the onset of psychotic symp-
toms (Colizzi et al., 2015a). Therefore, in both help-seeking groups, high
rates of substance use may have a detrimental effect on mental health.
Similar research has found help-seeking youth with mood disorders
were signiﬁcantly more likely to use substances such as cannabis and
tobacco if they presented with a high degree of distress and functional
disability (Scott et al., 2013; Scott et al., 2014). Additionally, previous re-
search with the UHR group suggests enhancement in mood is the pri-
mary reason for using substances (Gill et al., 2015). Despite some
signiﬁcant results, the majority of associations between substance in-
volvement and individual clinical variables were weak, and we did not
clearly identify any signiﬁcant clinical predictors of substance use.
Therefore, despite these factors being higher in the at-risk group, our
ﬁndings suggest there may be mediating variables not present in the
analysis that explain the increased risk of substance use in the UHR
group. We can speculate about several possibilities.sk for psychosis, Schizophr. Res. (2016), http://dx.doi.org/10.1016/
6 R. Carney et al. / Schizophrenia Research xxx (2016) xxx–xxxFirst, there may be a shared vulnerability to schizophrenia spectrum
disorders and substance use disorders. Although early interventionmay
prevent the onset of full threshold psychotic symptoms, it may be that
at-risk individuals are also at-risk for substance misuse. This possibility
arises from the high degree of heritability and comorbidity of substance
use disorders and schizophrenia (Chambers et al., 2001). An overlap in
genes which are implicated in schizophrenia and substance abuse,
such as those responsible for the modulation of dopamine systems
could account for this (Volkow, 2009).
Similarly, shared psychosocial vulnerabilities such as social depriva-
tion or childhood adversity have been found to increase the liability for
both factors (Howes et al., 2004; Redonnet et al., 2012). At-risk status
was not independently associated with cannabis use in our sample, de-
spite rates being higher in this group. Therefore, some people may pos-
sess other underlying vulnerabilities to psychosis which may be
moderated by the effects of substance use at an early age (Caspi et al.,
2005; Colizzi et al., 2015b; Henquet et al., 2008). For example, cannabis
usewhen combinedwith social adversity is believed to increase the risk
for psychotic disorder beyond just the individual factors (Stilo et al.,
2015).
Finally, substance use could increase vulnerability to schizophrenia,
whichmay explain the higher rates of substance use in those at-risk for
psychosis. Cannabis use, particularly at an early age, is associated with
the onset of psychotic symptoms (Donoghue et al., 2014; Helle et al.,
2016; Stefanis et al., 2013), and tobacco use may also contribute to the
onset of psychotic symptoms (Gurillo et al., 2015). Recent research
with the UHR group suggests that there is a dose-response relationship,
where cannabis abuse or dependence increases the risk for transition,
although this relationship is weakened when alcohol use is taken into
account (Auther et al., 2015; Kraan et al., 2015).
4.1. Study limitations
Our cross-sectional study means we cannot determine causality.
Longitudinal follow up will establish any variables which determine
continued substance use, as well as highlighting any relationship with
transition. Additionally, our sample may not represent the general
UHR population. Although the CAARMS positive subscales were used
to determine psychosis risk, additional criteria such as functioning and
genetic risk, were not applied. However, we note that Cornblatt et al.
used only the attenuated psychotic symptoms group in their recent
study (Cornblatt et al., 2015). Another limitation is that individuals pre-
sented to youth mental health clinics and may differ from traditional
help-seeking populations presenting to primary care. Finally, we did
not control for multiple comparisons, which may have increased the
risk of Type II error. As quantile median regression was not an accept-
able approach to use for cannabis involvement scores (due to a failure
of the models to converge), any conclusions derived about cannabis
use should be made with caution.
4.2. Clinical implications
The increased substance use observed in at-risk youth has clinical
implications. First, it places young people at increased risk of metabolic
disturbances if they do transition to a ﬁrst-episode of psychosis and re-
ceive anti-psychotic medication. Second, these behaviours are modiﬁ-
able, and young people may wish to engage in lifestyle interventions
such as smoking cessation programs. Regardless of whether an individ-
ual later experiences psychosis or not, the UHR phase represents an op-
portunity for early intervention to prevent orminimise future ill-health.
Third, high rates of unhealthy lifestyle factors may increase the risk of
psychosis (Di Forti et al., 2014; Gurillo et al., 2015). Co-morbid sub-
stance use disorders are common in people with schizophrenia
(Volkow, 2009), depression (Boschloo et al., 2011), and anxiety
(Conway et al., 2006). Therefore, promoting a healthier lifestyle and en-
couraging cessation of substances could improve outcome.Please cite this article as: Carney, R., et al., Substance use in youth at ri
j.schres.2016.08.0264.3. Conclusion
This current study adds to growing evidence suggesting increased
rates of substance use are common in young people presenting with
mental health difﬁculties, particularly those at-risk for psychosis. The
negative consequences of continued substance use may be more pro-
nounced in this group, who are already at risk for poor physical and
mental health in the future. Therefore, this phase is an important
stage to intervenewith lifestyle interventions to promote healthy living,
and has the potential to improve physical health, and beneﬁt mental
health and wellbeing.
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